{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:28:21Z","timestamp":1790630901001,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["ML41627"],"award-info":[{"award-number":["ML41627"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.msard.2021.103282","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:49:51Z","timestamp":1632779391000},"page":"103282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment"],"prefix":"10.1016","volume":"56","author":[{"given":"H.Phuong T.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resmi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. William","family":"Lindsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2021.103282_bib0001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13073-019-0640-z","article-title":"Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility","volume":"11","author":"Afrasiabi","year":"2019","journal-title":"Genome Med."},{"issue":"3","key":"10.1016\/j.msard.2021.103282_bib0002","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","article-title":"Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.msard.2021.103282_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002715","article-title":"Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to epstein-barr virus and multiple sclerosis","volume":"8","author":"Casiraghi","year":"2012","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.msard.2021.103282_bib0004","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/1352458511426816","article-title":"EBV-specific immune responses in patients with multiple sclerosis responding to IFNbeta therapy","volume":"18","author":"Comabella","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103282_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.msard.2018.02.029","article-title":"Could antiretrovirals be treating EBV in MS? A case report","volume":"22","author":"Drosu","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103282_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-018-0102-3","article-title":"Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity","author":"Harley","year":"2018","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.msard.2021.103282_bib0007","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2021.103282_bib0008","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/589714","article-title":"Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells","volume":"198","author":"Hoover","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.msard.2021.103282_bib0009","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jneuroim.2010.08.009","article-title":"Epstein-Barr virus and multiple sclerosis: cellular immune response and cross-reactivity","volume":"229","author":"Lindsey","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2021.103282_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584297","article-title":"Multiple sclerosis-like symptoms in mice are driven by latent \u03b3Herpesvirus-68 infected B cells","volume":"11","author":"M\u00e1rquez","year":"2020","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.msard.2021.103282_bib0011","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis","volume":"3","author":"Pender","year":"2018","journal-title":"JCI Insight"},{"issue":"1\u20132","key":"10.1016\/j.msard.2021.103282_bib0012","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jns.2013.03.002","article-title":"Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination","volume":"333","author":"Rostami","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2021.103282_bib0013","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/1744666X.2021.1847642","article-title":"The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review","volume":"16","author":"Ruprecht","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2021.103282_bib0014","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awy069","article-title":"T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention","volume":"141","author":"van Langelaar","year":"2018","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.msard.2021.103282_bib0015","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/eji.202048739","article-title":"The association of Epstein-Barr virus infection with CXCR3 (+) B-cell development in multiple sclerosis: impact of immunotherapies","volume":"51","author":"van Langelaar","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2021.103282_bib0016","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1001\/archneur.61.10.1613","article-title":"Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease","volume":"61","author":"Weiner","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2021.103282_bib0017","article-title":"Attenuated immune control of Epstein Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15","author":"Zdimerova","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.msard.2021.103282_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101388","article-title":"Teriflunomide\u2019s effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis","volume":"36","author":"Zivadinov","year":"2019","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:02:35Z","timestamp":1761901355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821005496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":18,"alternative-id":["S2211034821005496"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103282","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103282"}}